The stock of Outlook Therapeutics Inc. (NASDAQ:OTLK) increased by $0.13 on Tuesday to finish at $1.41, up 10.16 percent. The last five days have seen an average of 4,480,520 shares of common stock traded. 11 times new highs were reached in the current year, with a gain of $0.3300. The average number of shares traded over the last 20 days was 2,226,570, while the average volume over the last 50 days totaled 1,610,712.
OTLK stock dropped -18.50% since last month. On 08/25/23, the company’s shares reached a one-month low of $1.1400. The stock touched a high of $2.03 on 06/06/23, after rallying from a low of $0.80 in 52 weeks. The price of OTLK stock has risen by 30.56% or $0.3300 this year, reaching a new high 11 times. Still, the stock price is down -30.54% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
OTLK stock investors should be aware that Outlook Therapeutics Inc. (OTLK) stock had its last reported insider trading activity 132 days ago on Apr 20. On Apr 20, Chief Operations Officer Dagnon Terry sold 520,000 shares at $1.14 each. This transaction resulted in the insider making $590,200. On Jan 20, Evanson Jeff sold 267,000 shares at a price of US$1.11. After the transaction, the insider now owns 745,975 shares. Chief Commercial Officer Evanson Jeff had earlier sold 103,255 shares on Jan 19 for $1.22 a share. The transaction was completed for $125,971.
Financial Health
For the three months ended June 29, Outlook Therapeutics Inc.’s quick ratio was 0.90, while its current ratio was 0.90, indicating its inability to pay off its debt. Based on annual data, it had gross profit of $63.07 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. OTLK’s return on assets (ROA) during the last 12 months has been -127.20%. In the meantime, the return on equity (ROE) for the last 12 months was -818.70%.
Earnings Surprise
According to Outlook Therapeutics Inc.’s quarterly financial report for the quarter that ended June 29. A higher net income was reported in the quarter under review than the previous quarter. It was predicted that Outlook Therapeutics Inc.’s quarterly earnings would be -$0.08, but it ended up being -$0.05. EBITDA was -$18.13 million for the quarter. At the end of Outlook Therapeutics Inc.’s most recent quarter ended June 29, its liabilities totaled 49.95 million, while its total debt was $34.74 million. Equity owned by shareholders amounts to $260.25 million.
Technical Picture
Here’s a quick look at Outlook Therapeutics Inc.’s (OTLK) price momentum from a technical perspective. As of 29 August, the RSI 9-day stood at 50.83%, suggesting the stock is Neutral, with a 103.85% historical volatility rate.
The stochastic %K and %D were 25.60% and 14.00% respectively, while the average true range (ATR) was 0.1245. Based on the 14-day stochastic reading of 48.21%, the RSI (14) reading is 46.70%. On the 9-day MACD Oscillator, the stock is at -0.0172, and the 14-day reading is at -0.1020.
Analyst Ratings
In its analyst report released on July 13, 2023, CapitalOne began covering Outlook Therapeutics Inc. (NASDAQ: OTLK). The stock was rated as an Overweight by the brokerage firm. Analysts have assigned Outlook Therapeutics Inc. (OTLK) an Buy rating. OTLK is a stock that is recommended for selling by 0 brokerage firms, while 0 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 1 rate it overweight and 7 others recommend it as a buy.
What is OTLK’s price target for the next 12 months?
The current consensus forecast for the stock is between $4.00 and $10.00, with a median target price of $6.00. In analyzing these forecasts, the average price target given by analysts for Outlook Therapeutics Inc. (OTLK) is $6.44.
